Medigene Ag (MDGEF) 5.8500 $MDGEF
Global Gliosarcoma Clinical Trials Review, H2, 2013
M2 - Mon Jan 13, 10:28AM CST
Research and Markets (http://www.researchandmarkets.com/research/kxpcs7/gliosarcoma) has announced the addition of the "Gliosarcoma Global Clinical Trials Review, H2, 2013" report to their offering. This report provides elemental information and data relating to the clinical trials on Gliosarcoma. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Gliosarcoma. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Top Companies Participating in Gliosarcoma Therapeutics Clinical Trials - Actelion Ltd - Arno Therapeutics, Inc. - Biogen Idec Inc. - Celgene Corporation - Celldex Therapeutics, Inc. - DNAtrix, Inc. - Eli Lilly and Company - Exelixis, Inc. - MediGene AG - Merck & Co., Inc. For more information visit http://www.researchandmarkets.com/research/kx...liosarcoma
Genital Warts Global Clinical Trials Review, H2, 2013 Includes Players such as Helix Therapeutics LLC and MediGene AG
M2 - Thu Jan 09, 4:01AM CST
Research and Markets (http://www.researchandmarkets.com/research/ttmvbz/genital_warts) has announced the addition of the "Genital Warts (Condylomata Acuminata) Global Clinical Trials Review, H2, 2013" report to their offering. The clinical trial report, Genital Warts (Condylomata Acuminata) Global Clinical Trials Review, H2, 2013" provides data on the Genital Warts (Condylomata Acuminata) clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Genital Warts (Condylomata Acuminata). It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Genital Warts (Condylomata Acuminata). Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Companies Mentioned: -Anaconda Pharma -BioMAS Ltd. -Clinical Trial Overview of Helix Therapeutics LLC -Department of Biotechnology, India -G&E Herbal Biotechnology Co., Ltd. -Gilead Sciences, Inc. -Graceway Pharmaceuticals, LLC -Helix Therapeutics LLC -Huazhong University of Science & Technology -Karolinska Institutet -Medical Research Council -MediGene AG -Merck & Co., Inc. -The University of British Columbia -The University of Queensland -Universidad de Valparaiso -University of California, Los Angeles For more information visit http://www.researchandmarkets.com/research/tt...ital_warts About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Metastatic Adenocarcinoma of The Pancreas - Pipeline Review, H2 2013
M2 - Tue Nov 05, 9:30AM CST
Research and Markets (http://www.researchandmarkets.com/research/8xl6fp/metastatic) has announced the addition of the "Metastatic Adenocarcinoma of The Pancreas - Pipeline Review, H2 2013" report to their offering. 'Metastatic Adenocarcinoma of The Pancreas - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Metastatic Adenocarcinoma of The Pancreas, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Metastatic Adenocarcinoma of The Pancreas. Scope - A snapshot of the global therapeutic scenario for Metastatic Adenocarcinoma of The Pancreas. - A review of the Metastatic Adenocarcinoma of The Pancreas products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Metastatic Adenocarcinoma of The Pancreas pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Metastatic Adenocarcinoma of The Pancreas. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Metastatic Adenocarcinoma of The Pancreas pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Mentioned Gilead Sciences, Inc. MediGene AG Nanotherapeutics, Inc. Novartis AG Oncolytics Biotech Inc. Peregrine Pharmaceuticals, Inc. Threshold Pharmaceuticals, Inc. Axcentua Pharmaceuticals AB Eleison Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/8xl6fp/metastatic About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Cervical Cancer - Pipeline Review, H2 2013
M2 - Thu Sep 12, 8:54AM CDT
Research and Markets (http://www.researchandmarkets.com/research/lpg7wz/cervical_cancer) has announced the addition of the "Cervical Cancer - Pipeline Review, H2 2013" report to their offering. 'Cervical Cancer - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Cervical Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Cervical Cancer. Scope - A snapshot of the global therapeutic scenario for Cervical Cancer. - A review of the Cervical Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Cervical Cancer pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned F. Hoffmann-La Roche Ltd. Helix BioPharma Corp. Sanofi-Aventis GlaxoSmithKline plc Gilead Sciences, Inc. Daiichi Sankyo Company, Ltd Amorfix Life Sciences Ltd. MediGene AG Nanotherapeutics, Inc. Novartis AG Chong Kun Dang Pharmaceutical Taiho Pharmaceutical Co., Ltd. Zeria Pharmaceutical Co Ltd Genmab A/S CEL-SCI Corporation Advaxis, Inc. 3SBio Inc. Dendreon Corporation Transgene SA Antigen Express, Inc. Shantha Biotechnics Limited and many more... For more information visit http://www.researchandmarkets.com/research/lp...cal_cancer About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Global Rheumatoid Arthritis Report - Drug Pipeline Review
M2 - Tue Sep 03, 9:20AM CDT
Research and Markets (http://www.researchandmarkets.com/research/xw6rsc/rheumatoid) has announced the addition of the "Rheumatoid Arthritis - Pipeline Review, H2 2013" report to their offering. 'Rheumatoid Arthritis - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Rheumatoid Arthritis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Rheumatoid Arthritis. Scope - A snapshot of the global therapeutic scenario for Rheumatoid Arthritis. - A review of the Rheumatoid Arthritis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Rheumatoid Arthritis pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Featured - Alcon, Inc. - Bristol-Myers Squibb Company - Johnson & Johnson - Boehringer Ingelheim GmbH - F. Hoffmann-La Roche Ltd. - Biogen Idec Inc. - Amgen Inc. - Antares Pharma, Inc. - AstraZeneca PLC - Eli Lilly and Company - GlaxoSmithKline plc - Inovio Biomedical Corporation - MedImmune LLC - Isis Pharmaceuticals, Inc. - Biotest AG - Merck & Co., Inc. - Santen Pharmaceutical Co., Ltd. - Ablynx - Emergent BioSolutions Inc. - Novo Nordisk A/S - Infinity Pharmaceuticals, Inc. - Albany Molecular Research, Inc. - Plexxikon Inc. - ViaCord - arGentis Pharmaceuticals, LLC - Reliance Life Sciences Pvt. Ltd. - MediGene AG For more information visit http://www.researchandmarkets.com/research/xw6rsc/rheumatoid
Warts - Pipeline Review, H2 2012
M2 - Tue Jan 22, 3:02AM CST
Research and Markets (http://www.researchandmarkets.com/research/g637jc/warts_pipeline) has announced the addition of Global Markets Direct's new report "Warts - Pipeline Review, H2 2012" to their offering. 'Warts - Pipeline Review, H2 2012', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Warts, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Warts. Scope - A snapshot of the global therapeutic scenario for Warts. - A review of the Warts products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Warts pipel
Global Gliosarcoma Clinical Trials Review, H2, 2013
M2 - Mon Jan 13, 10:28AM CST
Research and Markets (http://www.researchandmarkets.com/research/kxpcs7/gliosarcoma) has announced the addition of the "Gliosarcoma Global Clinical Trials Review, H2, 2013" report to their offering. This report provides elemental information and data relating to the clinical trials on Gliosarcoma. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Gliosarcoma. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Top Companies Participating in Gliosarcoma Therapeutics Clinical Trials - Actelion Ltd - Arno Therapeutics, Inc. - Biogen Idec Inc. - Celgene Corporation - Celldex Therapeutics, Inc. - DNAtrix, Inc. - Eli Lilly and Company - Exelixis, Inc. - MediGene AG - Merck & Co., Inc. For more information visit http://www.researchandmarkets.com/research/kx...liosarcoma
Genital Warts Global Clinical Trials Review, H2, 2013 Includes Players such as Helix Therapeutics LLC and MediGene AG
M2 - Thu Jan 09, 4:01AM CST
Research and Markets (http://www.researchandmarkets.com/research/ttmvbz/genital_warts) has announced the addition of the "Genital Warts (Condylomata Acuminata) Global Clinical Trials Review, H2, 2013" report to their offering. The clinical trial report, Genital Warts (Condylomata Acuminata) Global Clinical Trials Review, H2, 2013" provides data on the Genital Warts (Condylomata Acuminata) clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Genital Warts (Condylomata Acuminata). It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Genital Warts (Condylomata Acuminata). Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Companies Mentioned: -Anaconda Pharma -BioMAS Ltd. -Clinical Trial Overview of Helix Therapeutics LLC -Department of Biotechnology, India -G&E Herbal Biotechnology Co., Ltd. -Gilead Sciences, Inc. -Graceway Pharmaceuticals, LLC -Helix Therapeutics LLC -Huazhong University of Science & Technology -Karolinska Institutet -Medical Research Council -MediGene AG -Merck & Co., Inc. -The University of British Columbia -The University of Queensland -Universidad de Valparaiso -University of California, Los Angeles For more information visit http://www.researchandmarkets.com/research/tt...ital_warts About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Metastatic Adenocarcinoma of The Pancreas - Pipeline Review, H2 2013
M2 - Tue Nov 05, 9:30AM CST
Research and Markets (http://www.researchandmarkets.com/research/8xl6fp/metastatic) has announced the addition of the "Metastatic Adenocarcinoma of The Pancreas - Pipeline Review, H2 2013" report to their offering. 'Metastatic Adenocarcinoma of The Pancreas - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Metastatic Adenocarcinoma of The Pancreas, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Metastatic Adenocarcinoma of The Pancreas. Scope - A snapshot of the global therapeutic scenario for Metastatic Adenocarcinoma of The Pancreas. - A review of the Metastatic Adenocarcinoma of The Pancreas products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Metastatic Adenocarcinoma of The Pancreas pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Metastatic Adenocarcinoma of The Pancreas. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Metastatic Adenocarcinoma of The Pancreas pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Mentioned Gilead Sciences, Inc. MediGene AG Nanotherapeutics, Inc. Novartis AG Oncolytics Biotech Inc. Peregrine Pharmaceuticals, Inc. Threshold Pharmaceuticals, Inc. Axcentua Pharmaceuticals AB Eleison Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/8xl6fp/metastatic About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Cervical Cancer - Pipeline Review, H2 2013
M2 - Thu Sep 12, 8:54AM CDT
Research and Markets (http://www.researchandmarkets.com/research/lpg7wz/cervical_cancer) has announced the addition of the "Cervical Cancer - Pipeline Review, H2 2013" report to their offering. 'Cervical Cancer - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Cervical Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Cervical Cancer. Scope - A snapshot of the global therapeutic scenario for Cervical Cancer. - A review of the Cervical Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Cervical Cancer pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned F. Hoffmann-La Roche Ltd. Helix BioPharma Corp. Sanofi-Aventis GlaxoSmithKline plc Gilead Sciences, Inc. Daiichi Sankyo Company, Ltd Amorfix Life Sciences Ltd. MediGene AG Nanotherapeutics, Inc. Novartis AG Chong Kun Dang Pharmaceutical Taiho Pharmaceutical Co., Ltd. Zeria Pharmaceutical Co Ltd Genmab A/S CEL-SCI Corporation Advaxis, Inc. 3SBio Inc. Dendreon Corporation Transgene SA Antigen Express, Inc. Shantha Biotechnics Limited and many more... For more information visit http://www.researchandmarkets.com/research/lp...cal_cancer About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Global Rheumatoid Arthritis Report - Drug Pipeline Review
M2 - Tue Sep 03, 9:20AM CDT
Research and Markets (http://www.researchandmarkets.com/research/xw6rsc/rheumatoid) has announced the addition of the "Rheumatoid Arthritis - Pipeline Review, H2 2013" report to their offering. 'Rheumatoid Arthritis - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Rheumatoid Arthritis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Rheumatoid Arthritis. Scope - A snapshot of the global therapeutic scenario for Rheumatoid Arthritis. - A review of the Rheumatoid Arthritis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Rheumatoid Arthritis pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Featured - Alcon, Inc. - Bristol-Myers Squibb Company - Johnson & Johnson - Boehringer Ingelheim GmbH - F. Hoffmann-La Roche Ltd. - Biogen Idec Inc. - Amgen Inc. - Antares Pharma, Inc. - AstraZeneca PLC - Eli Lilly and Company - GlaxoSmithKline plc - Inovio Biomedical Corporation - MedImmune LLC - Isis Pharmaceuticals, Inc. - Biotest AG - Merck & Co., Inc. - Santen Pharmaceutical Co., Ltd. - Ablynx - Emergent BioSolutions Inc. - Novo Nordisk A/S - Infinity Pharmaceuticals, Inc. - Albany Molecular Research, Inc. - Plexxikon Inc. - ViaCord - arGentis Pharmaceuticals, LLC - Reliance Life Sciences Pvt. Ltd. - MediGene AG For more information visit http://www.researchandmarkets.com/research/xw6rsc/rheumatoid
Warts - Pipeline Review, H2 2012
M2 - Tue Jan 22, 3:02AM CST
Research and Markets (http://www.researchandmarkets.com/research/g637jc/warts_pipeline) has announced the addition of Global Markets Direct's new report "Warts - Pipeline Review, H2 2012" to their offering. 'Warts - Pipeline Review, H2 2012', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Warts, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Warts. Scope - A snapshot of the global therapeutic scenario for Warts. - A review of the Warts products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Warts pipel
